Designing a more reasonable combination treatment plan based on the metabolic crosstalk between tumor and immune cells can avoid treatment failure and increase the effectiveness of PD-1/PD-L1 checkpoint blockade immunotherapy in more cancers. Here, CD274 is linked to neoplasm.